AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25740829
Drug: Belimumab therapy
RxNorm normalized name: Belimumab
DrugBank: Belimumab (DB08879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Belimumab therapy for 52 weeks
Trial: 29336179
Drug: Belimumab therapy
RxNorm normalized name: Belimumab
DrugBank: Belimumab (DB08879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Belimumab therapy
Trial: 25740857
Drug: Oral mucosal
RxNorm normalized name: Finafta Multi Oral Mucosal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral mucosal disease (NIH Oral Mucosal Score, OMS)
Trial: 25742165
Drug: mAb7F9 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mAb7F9 (200 mg/kg)
Trial: 25742165
Drug: METH (0.1-0.56
FDA approved: no
EMA approved: no
PMDA approved: no
Description: METH (0.1-0.56 mg/kg, s.c.)
Trial: 25742165
Drug: METH (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: METH (0.3 mg/kg, s.c.)
Trial: 25749662
Drug: Bortezomib 1.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib 1.3 mg/m² rapid intravenous infusion on days 1, 4, 8, and 11, followed by pegylated liposomal doxorubicin 30 mg/m² intravenous infusion on day 4, up to 6 cycles.
Trial: 25751105
Drug: Activin A
RxNorm normalized name: Activin A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activin A (ActA) concentrations in cachectic patients (CC)
Trial: 25751105
Drug: Myostatin (Mstn)
RxNorm normalized name: nystatin Oral Suspension [Mycostatin]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myostatin (Mstn) concentrations in cachectic patients (CC)
Trial: 25752885
Drug: Integrative care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrative care (AIC) program with ≥ 4 CM treatments
Trial: 25753361
Drug: Regorafenib at
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib at 160 mg/day, 3 weeks out of 4
Trial: 25753604
Drug: Parenteral Amino
RxNorm normalized name: parenteral amino acid 7 % comb no.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral Amino Acid Therapy (250 cc of AAs 3 times per week postdialysis for 8 weeks)
Trial: 25755291
Drug: BR-ibrutinib (bendamustine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BR-ibrutinib (bendamustine and rituximab with ibrutinib 420 mg daily)
Trial: 25755291
Drug: FCR-ibrutinib (fludarabine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FCR-ibrutinib (fludarabine, cyclophosphamide, and rituximab with ibrutinib 420 mg daily)
Trial: 25756303
Drug: CAPROS supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAPROS supplementation (500 mg b.i.d for 12 weeks)
Trial: 25757508
Drug: Platelet aggregation
RxNorm normalized name: Platelet aggregation inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet aggregation and secretion in response to exogenous agonists in patients with sepsis
Trial: 25757607
Drug: Prolonged-release oxycodone/naloxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged-release oxycodone/naloxone (PR OXN) for 12 weeks (median daily dose, 20 mg)
Trial: 25757607
Drug: Prolonged-release oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged-release oxycodone (PR OXY)
Trial: 25758261
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy (DAPT) interruption
Trial: 25758261
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy (DAPT) treatment
Trial: 25758746
Drug: Dasatinib with
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dasatinib with intrapatient dose escalation by 50 mg daily every cycle as tolerated
Trial: 25760881
Drug: Microvascular angina
RxNorm normalized name: INVESTIGATIONAL ANTI-ANGINA DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microvascular angina diagnosis and treatment
Trial: 25761109
Drug: Ipilimumab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipilimumab (3 mg/kg) administered in up to four cycles at 3-week intervals
Trial: 25762343
Drug: RG7356 (humanized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RG7356 (humanized anti-CD44 antibody)
Trial: 25762533
Drug: Atropine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine (5 µg/kg) administered intravenously
Trial: 25763783
Drug: TFV disoproxil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TFV disoproxil fumarate/FTC therapy
Trial: 25763866
Drug: N-Acetylcysteine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-Acetylcysteine (150 mg/kg body weight)
Trial: 25764096
Drug: 1 mL
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mL of blood in a single aerobic bottle
Trial: 25764096
Drug: 0.5 mL
RxNorm normalized name: ethanol 0.5 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mL in aerobic and anaerobic bottles (control)
Trial: 25764096
Drug: 1 mL
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mL in a single aerobic bottle
Trial: 25765333
Drug: Bumetanide 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bumetanide 0.05 mg/kg
Trial: 25765333
Drug: Bumetanide 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bumetanide 0.1 mg/kg
Trial: 25765333
Drug: Bumetanide 0.2
RxNorm normalized name: bumetanide 0.2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bumetanide 0.2 mg/kg
Trial: 25765333
Drug: Bumetanide 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bumetanide 0.3 mg/kg
Trial: 25765333
Drug: Bumetanide (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bumetanide (all doses)
Trial: 25766640
Drug: Anti-tumour necrosis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-tumour necrosis factor (TNF) treatment
Trial: 25768439
Drug: Pseudomonas aeruginosa-mannose-sensitive
RxNorm normalized name: Pseudomonas aeruginosa
DrugBank: Pseudomonas aeruginosa (DB19284)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pseudomonas aeruginosa-mannose-sensitive hemagglutinin (PA-MSHA) 1 mg administered subcutaneously every other day and capecitabine 1000 mg/m2 orally twice a day for 2 weeks on, 1 week off.
Trial: 25768671
Drug: Baseline copeptin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline copeptin level >21.4 pmol/L
Trial: 25768671
Drug: Stimulated copeptin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulated copeptin >4.9 pmol/L (at sodium levels >147 mmol/L)
Trial: 25768671
Drug: Stimulated AVP
RxNorm normalized name: AVP-21D9
DrugBank: AVP-21D9 (DB17798)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulated AVP >1.8 pg/mL
Trial: 29749403
Drug: Obinutuzumab-bendamustine (G-B)
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Obinutuzumab-bendamustine (G-B)
Trial: 25769620
Drug: Obinutuzumab-fludarabine-cyclophosphamide (G-FC)
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Obinutuzumab-fludarabine-cyclophosphamide (G-FC)
Trial: 25769961
Drug: Residents with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Residents with a statement of 'no psychotropic drug prescription' but had a prescription
Trial: 25771041
Drug: 0.5% DHEA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% DHEA (prasterone) administered daily intravaginally for 52 weeks
Trial: 25771402
Drug: Imatinib mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imatinib mesylate (standard dose: adult 400 mg daily; children 260 mg/m² daily)
Trial: 25771402
Drug: Imatinib mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imatinib mesylate (dose escalation regimen: adult 100 mg daily initial dose up to 200 mg daily maximum; children initial dose 65 mg/m² daily up to 130 mg/m² daily)
Trial: 25772231
Drug: Rotigotine transdermal
RxNorm normalized name: Rotigotine Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotigotine transdermal patch (Neupro) as add-on to oral PD treatment for ≥1 month
Trial: 25772231
Drug: Rotigotine transdermal
RxNorm normalized name: Rotigotine Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotigotine transdermal patch (Neupro)
Trial: 25772756
Drug: Motesanib 125
RxNorm normalized name: Motesanib
DrugBank: Motesanib (DB05575)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motesanib 125 mg QD with FOLFIRI
Trial: 25772756
Drug: Motesanib 125
RxNorm normalized name: Motesanib
DrugBank: Motesanib (DB05575)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motesanib 125 mg QD with FOLFOX
Trial: 25772756
Drug: Motesanib 125
RxNorm normalized name: Motesanib
DrugBank: Motesanib (DB05575)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motesanib 125 mg QD
Trial: 25773763
Drug: Rotigotine transdermal
RxNorm normalized name: Rotigotine Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotigotine transdermal patch (1, 2, and 4 mg/24 h)
Trial: 25774664
Drug: Insulin-resistant group
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin-resistant group (HOMA-IR ≥2.6)
Trial: 25774664
Drug: Insulin-sensitive group
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin-sensitive group (HOMA-IR <2.6)
Trial: 25775947
Drug: MCT +
RxNorm normalized name: MCT
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCT + treatment-as-usual (TAU)
Trial: 25777345
Drug: Sorafenib 200
RxNorm normalized name: sorafenib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib 200 mg orally b.i.d. with bortezomib 1 mg/m(2) intravenously on days 1, 4, 8, and 11 every 21 days.
Trial: 25779580
Drug: Sample collected
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sample collected at optimal time of 4 h after dose, in addition to trough concentration
Trial: 25781361
Drug: 1-year outpatient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-year outpatient intervention program based on exercise, behavior, and nutrition therapy
Trial: 25782122
Drug: New oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New oral anticoagulants (NOACs)
Trial: 25782401
Drug: Clinician assessment
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinician assessment of treatment response using Clinical Global Impression scale
Trial: 25782401
Drug: Patient assessment
RxNorm normalized name: EUA Patient Assessment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient assessment of treatment response using Subject Global Assessment scale
Trial: 25784682
Drug: Carfilzomib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carfilzomib plus melphalan and prednisone (CMP) at the maximal tolerated dose (MTD) of 36 mg/m².
Trial: 25784682
Drug: Carfilzomib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carfilzomib plus melphalan and prednisone (CMP) at the MTD of 36 mg/m².
Trial: 25785226
Drug: Dietary polyunsaturated
RxNorm normalized name: OMEGA-3 POLYUNSATURATES
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary polyunsaturated fatty acids (PUFAs) intake in hormone therapy (HT) group
Trial: 25785226
Drug: Dietary polyunsaturated
RxNorm normalized name: OMEGA-3 POLYUNSATURATES
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary polyunsaturated fatty acids (PUFAs) intake in non-hormone therapy (non-HT) group
Trial: 25785995
Drug: pH1N1 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pH1N1 vaccine (two double doses)
Trial: 25786035
Drug: Mineralocorticoid receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mineralocorticoid receptor antagonists (MRAs), n=101
Trial: 25786035
Drug: No mineralocorticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No mineralocorticoid receptor antagonists (MRA-Neg), n=101
Trial: 25787057
Drug: DMT adherence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMT adherence measured by medication possession ratio (MPR) >0.9
Trial: 25787057
Drug: DMT adherence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMT adherence measured by medication possession ratio (MPR) >0.5-<0.9
Trial: 25787057
Drug: DMT adherence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMT adherence measured by medication possession ratio (MPR) <0.5
Trial: 25787923
Drug: Ramucirumab 6,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramucirumab 6, 8, or 10 mg/kg Q2W
Trial: 25787923
Drug: Ramucirumab 15
RxNorm normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ramucirumab 15 or 20 mg/kg Q3W
Trial: 25787923
Drug: Ramucirumab (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramucirumab (all doses)
Trial: 25789614
Drug: Methacholine inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methacholine inhalation test (MIT)
Trial: 25789989
Drug: Omalizumab (anti-IgE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omalizumab (anti-IgE treatment) administered for 12 weeks
Trial: 25793152
Drug: Etanercept 50
RxNorm normalized name: etanercept 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept 50 mg weekly for 12 weeks
Trial: 25793933
Drug: Diethylcarbamazine and
RxNorm normalized name: diethylcarbamazine
DrugBank: Diethylcarbamazine (DB00711)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diethylcarbamazine and albendazole (DEC/Alb) - single dose
Trial: 25794243
Drug: Mobile Insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mobile Insulin Titration Intervention (MITI) - texting/phone call intervention
Trial: 25794535
Drug: Volasertib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volasertib plus cisplatin (100 mg/m(2))
Trial: 25795132
Drug: Gene-mediated cytotoxic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gene-mediated cytotoxic immunotherapy (GMCI) with AdV-tk + prodrug in Arm A
Trial: 25795132
Drug: Gene-mediated cytotoxic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gene-mediated cytotoxic immunotherapy (GMCI) with AdV-tk + prodrug in Arm B
Trial: 25795402
Drug: Doxorubicin (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin (60 mg/m²) followed by Trabectedin (1.1 mg/m²) and Pegfilgrastim (6 mg) every 3 weeks for up to six cycles
Trial: 25795637
Drug: Nintedanib 100-450
RxNorm normalized name: nintedanib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nintedanib 100-450 mg once daily (n = 40)
Trial: 25795637
Drug: Nintedanib 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nintedanib 250 mg b.i.d. (n = 11)
Trial: 25795637
Drug: Nintedanib (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nintedanib (various doses)
Trial: 26199039
Drug: Maximum tolerated
RxNorm normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Maximum tolerated dose (MTD)
Trial: 25795722
Drug: Resimmune (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resimmune (2.5 - 11.25 μg/kg intravenous infusion over 15 minutes)
Trial: 25798215
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acid supplements (1.5 g)
Trial: 25800136
Drug: Baseline glomerular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline glomerular filtration rate < 30 mL/min
Trial: 25800893
Drug: Decreasing minimal
RxNorm normalized name: Centipeda minima whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decreasing minimal residual disease levels between end of induction and week 7 of maintenance therapy
Trial: 25801562
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy including telaprevir
Trial: 25801567
Drug: Tenofovir disoproxil
RxNorm normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tenofovir disoproxil fumarate 300 mg once daily
Trial: 25801567
Drug: Low body
RxNorm normalized name: Lotion, Multi Ingredient Topical application Lotion [ALPHA GLOW BODY CARE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low body weight, low eGFR, concomitant use of ritonavir-boosted protease inhibitors
Trial: 25802729
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (diet/exercise alone or diet/exercise plus oral antihyperglycemic drug)
Trial: 25802932
Drug: Nimotuzumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimotuzumab (200 mg/m² weekly for 4 weeks, then concurrent with gemcitabine (800 mg/m²) or cisplatin (50 mg/m²) for 18 weeks, then maintenance every 2 weeks)
Trial: 25802932
Drug: Concurrent phase
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrent phase with chemotherapy (gemcitabine or cisplatin)
Trial: 25802932
Drug: Nimotuzumab (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimotuzumab (single agent during induction and maintenance phases)
Trial: 25803093
Drug: Bosutinib 500
RxNorm normalized name: bosutinib 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosutinib 500 mg + Rifampin 600 mg
Trial: 25803268
Drug: Histrelin subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histrelin subcutaneous implant
Trial: 25804941
Drug: G-CSF with/without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF with/without chemotherapy
Trial: 25804941
Drug: G-CSF without
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF without plerixafor
Trial: 25806291
Drug: Erlotinib treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib treatment with low/intermediate ROR1 levels
Trial: 25806291
Drug: Erlotinib treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib treatment with high ROR1 levels
Trial: 25806291
Drug: Chemotherapy treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy treatment with low/intermediate ROR1 levels
Trial: 25806291
Drug: Chemotherapy treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy treatment with high ROR1 levels
Trial: 25806291
Drug: Erlotinib treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib treatment with T790M mutation and low/intermediate ROR1 levels
Trial: 25806291
Drug: Erlotinib treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib treatment with T790M mutation and high ROR1 levels
Trial: 25806291
Drug: Chemotherapy treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy treatment with T790M mutation and low/intermediate ROR1 levels
Trial: 25806291
Drug: Chemotherapy treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy treatment with T790M mutation and high ROR1 levels
Trial: 25807932
Drug: Lisinopril (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (0.1 mg/kg/day)
Trial: 25809054
Drug: Comprehensive geriatric
RxNorm normalized name: CATHETER,EXTERNAL CONVEEN #5120 GERIATRIC/PEDIATRIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive geriatric assessments, clinical and diagnostic information, biological and molecular markers.
Trial: 25809731
Drug: NVP-AUY922 monotherapy
RxNorm normalized name: NVP
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NVP-AUY922 monotherapy
Trial: 25809824
Drug: Cabazitaxel (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabazitaxel (25 mg/m² every 3 weeks plus daily prednisolone)
Trial: 25810005
Drug: G-CSF primary
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF primary prophylaxis orders
Trial: 25810005
Drug: G-CSF orders
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF orders relative to physician's FN risk intervention threshold
Trial: 25812009
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg glipizide × 1
Trial: 25812009
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg metformin × 2 days
Trial: 25812924
Drug: Subretinal visual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subretinal visual implant (Alpha IMS)
Trial: 25815033
Drug: Passive control
RxNorm normalized name: RESPIRATORY TUBE 22MM PASSIVE R#1147378
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Passive control (no treatment)
Trial: 25818754
Drug: 4 contrast
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 contrast agents used in Coronary CT angiography
Trial: 25819643
Drug: Tremelimumab 10
RxNorm normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tremelimumab 10 mg/kg once every 4 weeks for six doses, then every 12 weeks until disease progression, unacceptable toxic effects, or refusal to continue treatment.
Trial: 25821795
Drug: 173*CC genotype
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 173*CC genotype
Trial: 25822727
Drug: Unicirc instrument
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unicirc instrument with topical lidocaine/prilocaine anesthetic
Trial: 25822820
Drug: Agalsidase alfa
RxNorm normalized name: Agalsidase alfa
DrugBank: Agalsidase alfa (DB15874)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Agalsidase alfa (agalα; 0.2 mg/kg every other week)